A. Amendments to the Specification:

Please delete the paragraph appearing at page 2, lines 20-26, beginning with "WO 01/07409 A1 relates to carbazole derivatives . . ."

Please add the following immediately after the title of the invention:

CROSS-REFERENCE TO RELATED APPLICATIONS:

This application is the National Stage of International Application No. PCT/CH02/00725, filed December 27, 2002, which claims the benefit of Switzerland Application No. 2381/01, filed December 31, 2001 and PCT/CH02/00429, filed August 5, 2002, the contents of which are incorporated by reference herein.

Please add the following new paragraph immediately prior to page 1, line 3, and after the Cross Reference to Related Applications, as follows:

FIELD OF THE INVENTION:

Please add the following new paragraph immediately prior to page 1, line 6, as follows:

BACKGROUND OF THE INVENTION:

WO 01/07409 A1 relates to carbazole derivatives whose general formula partially overlaps with the below formula I but does not specifically describe a single compound covered by the below formula I and, furthermore, does not contain any sufficiently concrete general pointers in the direction of compounds of the below formula I.

Please add the following new paragraph immediately prior to page 1, line 6, and after the Background of the Invention, as follows:

SUMMARY OF THE INVENTION:

Please add the following new paragraph immediately prior to page 3, line 7, as follows:

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS:

Please amend the section description for the claims on the top of page 60, as follows:

WHAT IS CLAIMED IS: ~~PATENT CLAIMS~~

Please add the following Abstract of the Disclosure, as follows:

ABSTRACT:

Pyrrolidone carboxamides of formula (I) where R^2=a group of formula (a) or (b), R^5=phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or $-NR^6R^7$ and R^1, X, R^3, R^4, R^6 and R^7 have the meanings given in the description and the claims, pharmaceutically applicable acid addition salts with basic compounds of formula (I), pharmaceutically applicable salts of acid compounds of formula (I) with bases, pharmaceutically applicable esters of hydroxy- or carboxy-group containing compounds of formula (I) and hydrates and solvates thereof, inhibit the interaction of neuropeptide Y (NPY) with one of the neuropeptide receptor subtypes (NPY-Y5) and are particularly suitable for the prevention and treatment of arthritis, diabetes and especially eating disorders and obesity. The above can be produced by known methods and converted into a galenic dosage form.